Spotlight on topical pimecrolimus in pediatric atopic dermatitis

American Journal of Clinical Dermatology

Volumn 11, Issue 4, 2010, Pages 295-298

  Yang, Lily P H ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH BEHAVIOR; HUMAN; OINTMENT; PEDIATRIC ATOPIC DERMATITIS; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; TOPICAL TREATMENT;

ADMINISTRATION, CUTANEOUS; CHILD; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY OF LIFE; TACROLIMUS; TREATMENT OUTCOME;

EID: 77952972578     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11204640-000000000-00000     Document Type: Short Survey

References (48)

1. Yang LPH, Curran MP. Topical pimecrolimus: a review of its use in the management of pediatric atopic dermatitis. Pediatr Drugs 2009; 11 (6): 407-426
2. Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006; 141 (3): 199-212
3. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999 Aug; 141 (2): 264-273
4. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children: Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group. Pediatrics 2002 Jul; 110 (1 Pt 1): e2-9
5. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug: Flare Reduction in Eczema with Elidel (Infants) Multicenter Investigator Study Group. J Allergy Clin Immunol 2002 Aug; 110 (2): 277-284
6. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005 Feb; 52 (2): 247-253
7. Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007 Nov; 157 (5): 954-959
8. Aschoff R, Schwanebeck U, Bräutigam M, et al. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol 2009 Jan; 18 (1): 24-29
9. Jensen J-M, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009 May; 123 (5): 1124-1133
10. Allen BR, LakhanpaulM, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 Nov; 88 (11): 969-973
11. Eichenfield LF, Ho V, Matsunaga J, et al. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. J Dermatol 2007 Apr; 34 (4): 231-236
12. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781-787
13. Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006 Feb; 15 (2): 138-141
14. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel®) in infants with atopic dermatitis: a multicenter, 3-week, open-label study. Pediatr Dermatol 2005 Sep-Oct; 22 (5): 465-471
15. Novartis. Elidel® (pimecrolimus) 1% cream: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/ pi/pdf/elidel.pdf [Accessed 2009 Oct 14]
16. Kaufmann R, Fö lster-Holst R, Hö ger P, et al. Onset of action of pimecrolimus cream 1%in the treatment of atopic eczema in infants. JAllergy Clin Immunol 2004 Nov; 114 (5): 1183-1188
17. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J AmAcad Dermatol 2002 Apr; 46 (4): 495-504
18. Hoeger PH, LeeK-H, Jautova J, et al. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial. Br J Dermatol 2009 Feb; 160 (2): 415-422
19. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142 (2): 155-162
20. Kempers S, Boguniewicz M, Carter E, et al.Arandomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004 Oct; 51 (4): 515-525
21. Sigurgeirsson B, Ho V, Ferrá ndiz C, et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis. J Eur Acad Dermatol Venereol 2008 Nov; 22 (11): 1290-1301
22. Siegfried E, Korman N, Molina C, et al. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis [published erratum appears in J Dermatolog Treat 2006; 17 (4): 256]. J Dermatolog Treat 2006; 17 (3): 143-150
23. Lübbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. NOBEL (New Online Based ELidel) Study Group. Am J Clin Dermatol 2006; 7 (2): 121-131
24. Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a >2000 patient study. J Eur Acad Dermatol Venereol 2008 Feb; 22 (2): 195-203
25. McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006 Mar; 20 (3): 248-254
26. Sunderkö tter C, Weiss JM, Bextermö ller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. JDtsch Dermatol Ges 2006 Apr; 4 (4): 301-306
27. Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002 Dec; 110 (6): 1133-1136
28. Staab D, Kaufmann R, Bräutigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol 2005 Sep; 16 (6): 527-533
29. De Backer M, Morren M-A, Boonen H, et al. Belgian observational drug utilization study of pimecrolimus cream 1% in routine daily practice in atopic dermatitis. Dermatology 2008 Jun 5; 217 (2): 156-163
30. Coyle D, Barbeau M. Cost effectiveness of Elidel in the management of patients with atopic dermatitis in Canada. J CutanMed Surg 2004Nov-Dec; 8 (6): 405-410
31. Ellis CN, Kahler KH, Grueger J, et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006; 7 (2): 133-139
32. Garside R, SteinK, Castelnuovo E, et al. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2005 Jul; 9 (29): iii, xi-xiii,1-230
33. Pitt M, Garside R, Stein K. A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br J Dermatol 2006 Jun; 154 (6): 1137-1146
34. Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Med Econ 2003; 6 (1-14): 1-14
35. Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. J Manag Care Pharm 2005 Jan-Feb; 11 (1): 66-73
36. Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pimecrolimus or tacrolimus. J Manag Care Pharm 2007 May; 13 (4): 349-359
37. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006 Jan; 117 (1): e118-28
38. Langley RGB, Luger TA, Cork MJ, et al. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and postmarketing surveillance. Dermatology 2007; 215 Suppl. 1: 27-44
39. Langley RGB, Eichenfield LF, Lucky AW, et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol 2008 May-Jun; 25 (3): 301-307
40. Papp KA, Werfel T, Fö lster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1%in infants and young children: a two-year study. J Am Acad Dermatol 2005 Feb; 52 (2): 240-246
41. Zuberbier T, Bräutigam M. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease. J Eur Acad Dermatol Venereol 2008 Jun; 22 (6): 718-721
42. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis [publish erratum appears in Dermatology 2005; 211 (3): 292]. Dermatology 2005; 211 (2): 174-187 (Pubitemid 41160263)
43. Hultsch T. Elidel® (pimecrolimus) cream 1%: safety update February, 2005 [online]. Available from URL: http://www.fda.gov/OHRMS/DOCKETS/ ac/05/slides/2005-4089s2-02-02-Novartis%20Core%20Safety%20(CS).pdf [Accessed 2009 Oct 14]
44. Ring J, Mö hrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008; 31 (3): 185-198
45. Orlow SJ. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Pediatr Drugs 2007; 9 (5): 289-299
46. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007 Apr; 127 (4): 808-816
47. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009; 219 (1): 7-21
48. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009 May; 123 (5): 1111-1116